Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
13F holders, Q4 2022
Institutional positions in Alvotech as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −3 vs. Q3 2022
- Shares held
- 18.7M
- −2.02M (−9.7%) vs. Q3 2022
- Total value
- $184.7M
- +$44.1M (+31.4%) vs. Q3 2022
- New holders
- 0
- 0 more added
- Sold out
- 3
- 3 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 72 | $157.4M |
| Q1 2026 | 57 | $57.3M |
| Q4 2025 | 49 | $78.1M |
| Q3 2025 | 66 | $127.9M |
| Q2 2025 | 53 | $156.0M |
| Q1 2025 | 51 | $159.2M |
| Q4 2024 | 45 | $199.6M |
| Q3 2024 | 32 | $178.2M |
| Q2 2024 | 31 | $174.0M |
| Q1 2024 | 22 | $172.4M |
| Q4 2023 | 18 | $196.8M |
| Q3 2023 | 19 | $159.7M |
| Q2 2023 | 17 | $133.5M |
| Q1 2023 | 17 | $244.6M |
| Q4 2022 | 11 | $184.7M |
| Q3 2022 | 14 | $140.6M |
| Q2 2022 | 17 | $157.8M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Alvotech; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 2,582 | $25.8K | 0.00% | −8,157−76.0% | Reduced |
| Gamco Investors, Inc. Et Al | 13,447 | $134.5K | 0.00% | 00.0% | Unchanged |
| Lodbrok Capital LLP | 504,382 | $2.08M | 0.83% | −1,134,507−69.2% | Reduced |
| Farallon Capital Management, L.L.C. | 500,000 | $5.00M | 0.03% | 00.0% | Unchanged |
| Oaktree Fund Advisors, LLC | 667,367 | $6.67M | 9.97% | 00.0% | Unchanged |
| Temasek Holdings (Private) Ltd | 1,000,000 | $10.0M | 0.06% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 1,000,000 | $10.0M | 0.42% | 00.0% | Unchanged |
| Morgan Stanley | 1,039,920 | $10.4M | 0.00% | 00.0% | Unchanged |
| Sculptor Capital LP | 1,086,347 | $11.1M | 0.21% | 00.0% | Unchanged |
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 6,338,660 | $63.4M | 0.69% | 00.0% | Unchanged |
| Bracebridge Capital, LLC | 6,595,065 | $66.0M | 25.04% | −386,322−5.5% | Reduced |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −463,320−100.0% | Sold out |
| Narwhal Capital Management | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,003−100.0% | Sold out |